Pneumocystis carinfi is an important cause of pneumonitis in the immunosuppressed host. Little is known, however, about the biology of this organism. This report demonstrates that a MAb, M5E12, previously shown to be directed against a surface antigen that is present on rat-, rabbit-, ferret-, and human-derived P. carinji, is capable of hindering the development of P. carinii pneumonitis in animal models of this infection when administered throughout the period of immunosuppression. It appears that MAb M5E12 thus has identified a surface antigen of P. carinfi that is important in host-parasite interactions.
Introduction
In spite of the fact that Pneumocystis carini is a well-recognized cause of pneumonia in immunosuppressed patients, relatively little is known about the biology of this organism or about the immunopathogenesis of P. carinii pneumonitis (PCP).' Information about P. carinii has been greatly limited because of the inability to establish long-term or cell-free cultures of the organism and by the lack of specific, well-characterized serologic reagents (1) . Observations made from animal models have led to the assumption that cell-mediated immunity is crucial in protection from PCP, whereas humoral immunity is of little or no significance (2) (3) (4) . A role for humoral immunity, however, is suggested by the finding that natural infection with P. carinii occurs in humans with pure humoral as well as cellular immune defects (5) , and that experimental animals develop both systemic and local antibody responses during recovery from PCP (6) . In addition, passive administration of rabbit serum obtained after immunization with P. carinm delayed death from PCP in one study using nude mice (2) .
Highly specific murine MAbs to P. carinii can be produced without the need for culturing or purifying these organisms (7) . Characterization of the binding specificity of these and other MAbs has established that they generally react with P. carinii that is derived only from the animal species from which the immunizing organisms were obtained (7, 8 cies (7, 8) . MAb M5E 12 has been shown to bind to P. carinji of rat, rabbit, ferret, and human origin (7) . The surface antigen of ferret-derived P. carini recognized by this IgM MAb has been partially characterized and is a glycoprotein, containing disulfide linkages, which is bound by Con A and wheat germ agglutinin (unpublished observations). Because the epitope recognized by MAb M5E12 appears to be conserved on P. carini obtained from diverse hosts, it was a likely monoclonal for testing the effect of passive antibody immunoprophylaxis in the ferret and rat models of PCP (7, 9) . In both ofthese models, the animals develop spontaneous PCP upon immunosuppression. Within 2 wk PCP is demonstrable in the ferrets (unpublished observations); rats require at least 6-8 wk of immunosuppression before PCP is evident.
Methods
Passive immunoprophylaxis offerret PCP. For these experiments, young ferrets weighing -0.5-0.9 kg (Marshall Research Animals, Inc., North Rose, NY) were immunosuppressed by placing 2 mg/liter dexamethasone (Elkins-Sinn, Inc., Cherry Hill, NJ) in their drinking water as described for the rat model (7) . The animals were maintained on steroids throughout the duration of these experiments. MAb M5E12 and control IgM MAb 5M IH9, directed against the capsular polysaccharide ofH. influenzae type b (10), were prepared by saturated ammonium sulfate precipitation of ascites fluid followed by extensive dialysis against PBS. MAb 5MIH9 was chosen because it is ofthe same isotype as MAb M5E12 and it does not bind to P. carinii, as determined by immunofluorescence. The amount of IgM protein in each preparation was approximated by an RIA and the MAb preparations were also titered against P. carinhi by indirect immunofluorescence assay (7) . At the end of each experiment, the animals were killed and their lungs removed. To count the number of P. carinji cysts, 1 g of lung was carefully homogenized, stained with toluidine blue 0, coded, and then the cysts were counted as described (7).
Two experiments were performed in ferrets. In the first set of experiments, steroid-induced, immunosuppressed ferrets were given weekly intravenous injections of either MAb M5E12 or 5MIH9, at a dosage of -300 fig IgM/kg. This arbitrary dosage was based on the volume of MAb M5E12 that could be easily administered intravenously. Antibody administration was begun during the first week of immunosuppression. 1 wk after the eighth injection of antibody, the animals were killed and the number of P. carinii cysts in their lungs was counted. In the second experiment, animals were injected three times per week with MAb M5E12 at a dosage of -200 Mg IgM/kg. Control animals again received antibody 5M IH9, but this time the dosage of IgM was -10-fold higher than that received by the experimental group. Treatments were continued for 3 wk (nine injections). 3 d after the last injection, the animals were killed and the extent of PCP was quantitated.
Passive immunoprophylaxis of murine PCP. Sprague-Dawley rats (Harlan Sprague Dawley, Inc., Indianapolis, IN), weighing 200-300 g, were used to determine the effect of passively administered MAb M5E12 on this widely used animal model of PCP. The rats, immunosuppressed identically to the ferrets, received 200Mg IgM/kg ofME 12 i.p. once weekly for 3 wk. Starting with the fourth week ofimmunosuppression, the dosage of antibody was increased to 300 ,g IgM/kg administered thrice weekly for 9 wk. Control animals for this experiment received 0.5 ml/kg once per week of an irrelevant IgG MAb (11) prepared from ascites fluid. After the twelfth week of immunosuppression rats were killed and the total number ofP. carinii cysts in the lungs of each animal was quantitated as noted above.
Western blot analysis. Organisms obtained from ferrets that received either MAb M5E12 or control MAb 5MIH9 were examined for the presence of the surface antigen recognized by MAb M5E12 by Western blot. The specificity of this Western blot for a P. carinii antigen has been previously described (7) . The only modification of the Western blot used in this study was that the organisms were solubilized by boiling for 15 min in the cracking buffer rather than by sonication.
Results
As can be seen in Table I , passive immunoprophylaxis of ferrets with MAb M5E12 resulted in a marked reduction in the number of P. carinii organisms present in their lungs. In the first experiment, in which antibody was administered once weekly over a period of 2 mo, ferrets receiving MAb M5E12 had a 20-fold reduction in the number ofP. carinli per gram of lung tissue (P = 0.02; Mann-Whitney rank sum test). Likewise, animals receiving MAb M5E12 twice weekly, but for a total duration of only 3 wk, had a 10-fold reduction in the number of P. carinii when compared with control animals receiving MAb 5M1H9 (P = 0.13; Mann-Whitney rank sum test). When analyzed together, the two ferret experiments show that administration of MAb M5E12 resulted in a 90% reduction in the geometric mean number of organisms present in 1 g of lung tissue from 4.1 X 106 organisms/g in the control group to 3.4 X 105 organisms/g in the experimental group (P = 0.01; Mann-Whitney rank sum test).
A parallel experiment was performed to examine the ex- There was a similar reduction in the number of organisms present in the lungs of rats receiving passive immunoprophylaxis with MAb M5E 12 (Table II) . Rats receiving MAb M5E 12 had an approximately fivefold reduction in the number of organisms when compared with control animals (P = 0.002 by Mann-Whitney rank sum test).
Three ferrets (Table I, animals No. 661 , 666, and 670) clearly received no benefit from MAb M5E12. The reason for this is unclear, but may have important biologic implications. To exclude the possibility of antigenic modulation or variation, which is common among protozoan parasites, (12) Western blot analysis was performed on P. carinii obtained from ferrets in each group. Fig. 1 clearly demonstrates that when an equal number of P. carinii is solubilized, the 11 sion of the antigen recognized by MAb M5E12 on organisms obtained from these two-species. When titered by immunofluorescence assay MAb M5E12 has an -100-fold higher titer when ferret P. carinii are used as the target instead of rat P. carinii. Likewise, when analyzed by Western blot, MAb M5E12 produces a much stronger blot with ferret-derived P. carini compared with an equal number of rat-derived P. carinmi (7) . Finally, the pathology in the ferret model of PCP is an interstitial pneumonitis without the foamy alveolar exudates typically seen in rat PCP (9) . Whether these differences contributed to the more pronounced effect in the ferret model is not known.
There are several possible explanations for why the administration of MAb M5E12 did not completely prevent the development of PCP in this system. First, the animals are maintained on immunosuppressive therapy throughout the experiment, so that administration of relatively small amounts of an MAb to a single epitope on P. carinii may not allow for sufficient immunoreconstitution to prevent this infection altogether. Secondly, while MAb M5E12 clearly recognizes cyst forms of P. carini (7) , immunofluorescent assays on P. carinmi-infected lung lavage that has been passed through 3.0-and 1.2-pm filters demonstrate staining of structures consistent in size with trophozoites (unpublished observation). It is possible that MAb in SE 12 may exert its pIotective effect, e.g., complement-mediated cell lysis or inhibition of attachment, on only the trophozoite stage (13) . Any trophozoite that escapes attack by MAb M5E12 thus will go on to produce a mature cyst which will then give rise to eight additional organisms. As demonstrated by Fig. 1 , antigenic modulation does not explain the failure to totally protect against PCR' Further studies will be necessary to determine the mechanism of protection afforded by MAb M5E12. Whether the results described here can be improved by alteration in dosages of antibody, adding MAbs directed against other surface antigens, or by combination immunotherapy using other-biologic response modifiers will need to be determined.
Besides indicating that humoral immunity to P. carinii merits further investigation, these studies also give the first specific information yet available about antigens on the surface of P. carinii. Several investigators have now reported
